33rd week of 2022 patent applcation highlights part 9 |
Patent application number | Title | Published |
20220257566 | OXYMETAZOLINE COMPOSITIONS - The present disclosure is directed to compositions comprising oxymetazoline and methods of stabilizing oxymetazoline compositions for long term storage. | 2022-08-18 |
20220257567 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CORONAVIRUS DISEASE-19 - The present invention relates to a pharmaceutical composition for preventing or treating coronavirus disease 2019, and more specifically to a pharmaceutical composition for preventing or treating coronavirus disease 2019 found by drug repositioning technology using drug virtual screening technology. The pharmaceutical composition for preventing or treating coronavirus disease 2019 according to the present invention is a composition obtained by finding new uses for drugs, which have already been proven effective, for preventing or treating coronavirus disease 2019 by drug repositioning technology. The pharmaceutical composition is useful because it has significantly lower side effects than new drugs and can be rapidly applied to clinical practice. | 2022-08-18 |
20220257568 | TREATMENT OF OCULAR DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS - The present disclosure relates to the discovery that certain diseases of the eye that profoundly affect the human visual system and, as a result, quality of life, may be treated using Edonentan or A-182086. Edonentan or A-182086 can be used alone or in combination with an intra-ocular pressure (TOP) reducing agent, a neuroprotective agent, an anti-VEGF agent, or all, for example. Using Edonentan or A-182086, alone or in combination with an additional agent, provides increased perfusion to the retina in certain diseases and reduces damage to retinal cells. | 2022-08-18 |
20220257569 | INDOLE-OXADIAZOLE COMPOUNDS AND THEIR THERAPEUTIC USE - The present application pertains to methods of using indole-oxadiazole compounds of Formula I to modulate cannabinoid receptor activity: I In particular diseases, disorders or conditions that benefit from modulating cannabinoid receptor activity, such as non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), schizophrenia, bipolar disorder, psychosis, metabolic syndrome, type-2 diabetes, dyslipidaemia, obesity, eating disorders, cardiovascular diseases and disorders, and other conditions as described herein, may be treated. Also included in the present application are certain novel compounds of Formula Ia and pharmaceutical compositions comprising these compounds. | 2022-08-18 |
20220257570 | CALPAIN INHIBITORS AND USES THEREOF FOR TREATING NEUROLOGICAL DISORDERS - Methods of treating neurological diseases and disorders associated with protein aggregation using calpain inhibitors are provided. Said neurological diseases associated with protein aggregation include polyglutamine expansion diseases such as Huntington's disease, Machado-Joseph disease, and spinocerebellar ataxias. | 2022-08-18 |
20220257571 | INHIBITOR OF MAP KINASE INTERACTING SERINE/THREONINE KINASE 1 (MNK1) AND MAP KINASE INTERACTING SERINE/THREONINE KINASE 2 (MNK2), CANCER THERAPY AND THERAPEUTIC COMBINATIONS - The present invention describes 4,6-diphenyl-1H-pyrazolo[3,4-b]pyridin-3-amine (EB1), or a pharmaceutically acceptable salt thereof, as a selective MNK inhibitor for use in the treatment of cancers of an hormone-dependent organs, including triple-negative breast cancer, prostate cancer and other referable cancers with p-eIF4E overexpression due to increased MNK activity. The invention also includes particular therapeutic combinations including the 4,6-diphenyl-1H-pyrazolo[3,4-b]pyridin-3-amine. | 2022-08-18 |
20220257572 | METHODS OF TREATING EPILEPSY - In various aspects and embodiments the invention provides a method of treating epilepsy in a subject in need thereof, the method comprising providing to the subject an effective amount of an FLNA modulator. In various embodiments, the FLNA modulator is PTI-125 or kartogenin. In various embodiments, the epilepsy is epilepsy associated with focal cortical dysplasia (FCD) type II or tuberous sclerosis complex (TSC). | 2022-08-18 |
20220257573 | SUSTAINED-RELEASE MICROGEL OINTMENTS WITH HIGH DRUG LOADING AND PREPARATION METHODS AND USES THEREOF - Disclosed is a sustained-release microgel ointment with high drug loading and a preparation method and use thereof. HTCC aqueous solution and HA aqueous solution are mixed uniformly to obtain the microgel aqueous solution. A drug is mixed with the microgel aqueous solution and concentrated, and a thickening agent is added and mixed evenly to obtain the sustained-release microgel ointment with high drug loading. The HA and HTCC form a microgel through electrostatic action, which is safe and convenient. The concentration step increases the concentration of the drug solution outside the microgel, which can increase the drug loading of the microgel. Drugs not loaded in the microgel inhibited the drug from being released from the microgel, prolonging the sustained release time of the microgel. The thickener transforms the drug-loaded microgel suspension into a paste, facilitating to applying the drug on the skin surface. Meanwhile, the drug added can be used at 100%, reducing the cost of microgel ointment. The ointment can be used to prepare a medicine for treating histamine-independent pruritus and analgesia. | 2022-08-18 |
20220257574 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-- 3-YL)-2-FLUOROPHENYL)-3-PHENYLUREA - Provided herein are low impurity compositions comprising a compound represented by Formula (I): | 2022-08-18 |
20220257575 | METHODS OF TREATING GASTROINTESTINAL STROMAL TUMORS - The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof. | 2022-08-18 |
20220257576 | METHODS AND COMPOSITIONS FOR TREATING OBESITY AND/OR DIABETES AND FOR IDENTIFYING CANDIDATE TREATMENT AGENTS - Provided are methods and compositions for identifying candidate agents for treatment of obesity, liver disease, and/or diabetes. Such methods include, e.g., contacting a mammalian cell or cell population with a test agent, and measuring an expression level and/or activity level of ClpP in the mammalian cell or in cells of the cell population. Also provided are methods and compositions for treating an individual (e.g., one who is obese and/or has diabetes). Treatment methods include administering an inhibitor of ClpP to the individual (e.g., to prevent or reduce weight gain, to increase insulin sensitivity, and/or to increase glucose tolerance). | 2022-08-18 |
20220257577 | EZH2 INHIBITION IN COMBINATION THERAPIES FOR THE TREATMENT OF CANCERS - Provided herein are methods for treating advanced relapsed solid tumors using 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2, 4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide; or a pharmaceutically acceptable salt thereof. Also provided herein are methods of treating cancers (e.g., solid tumors) using 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide; or a pharmaceutically acceptable salt thereof; and a second agent selected from a topoisomerase inhibitor, a DNA alkylating agent, and an androgen receptor signaling inhibitor. | 2022-08-18 |
20220257578 | COMPOSITION AND METHOD FOR TREATING CANDIDA AURIS INFECTION - infection in a subject is treated with 4-{3-[4-(3-{4-[amino(imino)methyl]phenoxy}propyl)-1-piperidinyl]propoxy}benzamidine (T-2307) or a pharmaceutically acceptable salt thereof. | 2022-08-18 |
20220257579 | METHODS AND COMPOSITIONS FOR IMPROVING SLEEP - Compositions suitable for oral use (e.g., oral thin film) containing various excipients and a combination of melatonin, caryophyllene, GABA, L-theanine, and vitamin B | 2022-08-18 |
20220257580 | TREATMENT OF C3 GLOMERULOPATHY USING A C5A INHIBITOR - Methods of treating certain human patient populations suffering from or susceptible to C3 glomerulopathy comprising administering to the human an effective amount of a C5aR antagonist are provided. | 2022-08-18 |
20220257581 | Treatment of Cancer - Provided herein are methods of treating a hematologic cancer in a subject in need thereof, comprising administering to the subject an effective amount of alvocidib, or prodrug thereof, or a pharmaceutically acceptable salt of the foregoing. The subject is in complete remission from the hematologic cancer and measurable residual disease (MRD)-positive following administration of a prior therapy that does not include alvocidib, or a prodrug thereof, or a pharmaceutically acceptable salt of the foregoing, and is MRD-negative following administration of alvocidib, or a prodrug thereof, or a pharmaceutically acceptable salt of the foregoing. Other methods are also provided in accordance with other aspects of the invention. | 2022-08-18 |
20220257582 | TREATMENT FOR SYNUCLEINOPATHIES - A method of treating or preventing synucleinopathies in a human subject comprising administering a therapeutically effective amount of a compound of Formula 1, | 2022-08-18 |
20220257583 | Compositions and Methods for the Treatment of Intracranial Diseases - Provided herein are compositions and methods for enhancing egress of T-cells from bone marrow of a subject in need thereof. Also provided are compositions and methods for the treatment of diseases characterized by reduced surface display of sphingosine-1-phosphate receptor 1 (S1P1), as well as methods of diagnosis/prognosis related to surface display of SIP 1. Methods of treating cancer are also provided. | 2022-08-18 |
20220257584 | METHODS OF TREATING INFECTIONS IN OVERWEIGHT AND OBESE PATIENTS USING ANTIBIOTICS - The present disclosure relates generally to methods of treating infections in overweight or obese patients using antibiotics. | 2022-08-18 |
20220257585 | HYALURONIC ACID-BASED OPHTHALMIC DRUG DELIVERY SYSTEM, AND METHOD FOR PRODUCING SAME - Disclosed is an ophthalmic drug delivery system intended for insertion into an eye, the ophthalmic drug delivery system containing: a carrier comprising crosslinked hyaluronic acid; and a drug loaded in the carrier. Also disclosed is a method for producing an ophthalmic drug delivery system, the method comprising steps of: preparing a first solution containing hyaluronic acid and water; preparing a second solution containing 1,4-butanediol diglycidyl ether (BDDE) and water; sterilizing the first solution and the second solution separately; preparing a third solution by mixing the sterilized first solution and second solution together; and polymerizing the hyaluronic acid by incubating the third solution. | 2022-08-18 |
20220257586 | METHODS FOR TREATING IMMUNODEFICIENCY DISEASE - The present invention relates to methods of treating patients with WHIM syndrome or related disorders, such as myelokathexis, in which X4P-001 is administered in order to reduce the activity of CXCR4. The methods demonstrate surprising effectiveness, with comparatively little toxicity. | 2022-08-18 |
20220257587 | NLRP3 MODULATORS - The present invention provides compounds of Formula (I): | 2022-08-18 |
20220257588 | METHODS OF PREVENTING OR TREATING FLAVIVIRUS VIRUS INFECTIONS AND METHODS OF INHIBITING THE ENTRY OF FLVIVIRUS, ENTEROVIRUS OR LENTIVIRUS INTO HOST CELLS - A method of preventing or treating a subject suffering from a flavivirus infection by administering an effective amount of berbamine or its analogue to the subject, berbamine has a structure of Formula (I), wherein the flavivirus infection is caused by Japanese encephalitis virus, Zika virus or Dengue virus. A method of inhibiting the entry of a flavivirus, an enterovirus and/or a lentivirus into host cells includes contacting the host cells with an effective amount of berbamine of its analogue, berbamine has a structure of Formula (I), wherein the flavivirus is Japanese encephalitis virus, Zika virus or Dengue virus. | 2022-08-18 |
20220257589 | DRUG CARRIER AND PREPARATION METHOD THEREOF - This present invention relates to a drug carrier comprising a polymer of γ-glutamyl transpeptidase catalyzing hydrolysis-induced charge reversal, and a method for preparing the same. It can have a long circulation time in the blood, and can realize a charge reversal from negatively charged or the neutral to positively charged around the tumor blood vessel region, so that the positively charged polymer effectively penetrates deep into the tumor tissue, fast entering into the tumor cells, and greatly improves the therapeutic effect of the drug on the tumor. This overcomes the problems of slow diffusion of traditional polymer drug carriers in tumors and weak interaction with tumor cells, and has great significance in the field of anticancer treatment in the medical field. | 2022-08-18 |
20220257590 | METHOD OF TREATING DYSKINESIA - Methods of treating patients with dyskinesias, by administering a therapeutically effective amount of a dual-action μ-opioid receptor antagonist/κ-opioid receptor agonists or prodrug thereof to a subject in need thereof, sufficient to mitigate the dyskinesia. Alternatively, a combination of both a μ-opioid receptor antagonist or prodrug thereof, and a κ-opioid receptor agonist or prodrug thereof can be administered, either together or separately. | 2022-08-18 |
20220257591 | Methods for Treating Visceral Fat Conditions - Disclosed are methods and compositions for treating visceral fat conditions and/or metabolic syndrome using combinations of naltrexone and bupropion. | 2022-08-18 |
20220257592 | METHODS OF TREATING CANCER - Provided herein are methods of treating cancer in a patient in need thereof includes administering to the patient a therapeutically effective amount of entrectinib wherein the patient has impaired hepatic function and methods of managing adverse reactions of administration of entrectinib in a patient. | 2022-08-18 |
20220257593 | CARABACHOL-BROMONIDINE FORMULATION TO ENHANCE ANTI-PRESBYOPIA EFFECTS - Use of topical carbachol in combination with brimonidine to create optically beneficial miosis to temporarily treat presbyopia. A pharmaceutical formulation is used comprising a therapeutically effective amount of carbachol, or a pharmaceutically acceptable salt thereof, in combination with brimonidine, or a pharmaceutically acceptable salt thereof, specifically combined with permeation enhancers and excipients to increase efficacy and reduce ocular surface toxicity and improve tolerability. | 2022-08-18 |
20220257594 | TRANSITIONING PATIENTS TREATED FOR PULMONARY ARTERIAL HYPERTENSION TO SELEXIPAG - The present disclosure provides methods of transitioning a patient being treated for pulmonary arterial hypertension with a non-selexipag prostacyclin pathway agent (PPA) to selexipag. | 2022-08-18 |
20220257595 | MACITENTAN FOR USE IN TREATING PORTOPULMONARY HYPERTENSION - The present invention provides methods for treating portopulmonary hypertension, comprising administering to a patient in need thereof, a therapeutically effective amount of macitentan. Preferably, the methods are clinically proven safe and/or effective. Also provided are methods of improving liver transplant perioperative mortality risk category, improving MELD exception eligibility, and reducing the risk of removal from a liver transplant waitlist in a patient with portopulmonary hypertension and liver disease, comprising administering to a patient in need thereof a therapeutically effective amount of macitentan. | 2022-08-18 |
20220257596 | METHODS FOR TREATING MEIBOMIAN GLAND DYSFUNCTION WITH LIVER X RECEPTOR AGONISTS - The present invention provides methods for treating meibomian gland dysfunction using liver X receptor (LXR) agonists. | 2022-08-18 |
20220257597 | Methods of Administering Elagolix - The present disclosure relates to the use of GnRH receptor antagonists for the treatment of endometriosis, uterine fibroids, polycystic ovary syndrome (PCOS), or adenomyosis. In particular, the present disclosure describes methods for treating such gynecological disorders, where the methods involve administration of elagolix and may further involve co-administration of a CYP2B6 substrate (e.g., bupropion) or a CYP2C19 substrate (e.g., omeprazole) or a CYP3A4 substrate (e.g., ethinyl estradiol and/or levonorgestrel). | 2022-08-18 |
20220257598 | Use of 2-Phenyl-6-(1H-Imidazol-1-YL) Quinazoline for Treating Neurodegenerative Diseases, Preferably Alzheimer's Disease - The invention concerns a compound of formula 2-phenyl-6-(1H-imidazol-1-yl)quinazoline or a pharmaceutically acceptable salt thereof for use in the treatment of a neurodegenerative disease. The neurodegenerative disease is a disease selected from the group consisting of Alzheimer's disease, Lewy body dementia, frontotemporal dementia, amyotrophic lateral sclerosis, Huntington disease, prion diseases, HIV-associated dementia and any form of cognitive disorders linked to neurodegeneration, preferably Alzheimer's disease. | 2022-08-18 |
20220257599 | METHODS USEFUL IN TREATING CANCERS HARBORING A KRAS OR HRAS MUTATION OR AMPLIFICATION - The present technology is directed to methods useful in treating cancer, slowing growth of a tumor, reversing growth of a tumor, slowing growth of a neoplasm, reversing growth of a neoplasm, slowing proliferation of a neoplasm, and/or reversing proliferation of a neoplasm, for cancers, tumors, and neoplasms harboring a constitutively active variant of one or both of KRAS or HRAS, where the constitutively active variant is a gain of function mutation, a duplication, or a gene amplification. | 2022-08-18 |
20220257600 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A JAK OR OTHER KINASE INHIBITOR - This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a JAK or other kinase inhibitor. | 2022-08-18 |
20220257601 | INHIBITORS OF PRC1 FOR TREATMENT OF CANCER - Disclosed herein are compounds and methods for the inhibition of the RNF1 or RNF2 subunit of polycomb repressive complex 1 (PRC1) for the treatment of metastatic cancer, such as metastatic castration-resistant prostate cancer. The inhibitors can be combined with checkpoint inhibitors such as PD-1 inhibitors, PD-L 1 inhibitors, or CTLA-4 inhibitors. | 2022-08-18 |
20220257602 | ALKYNE DERIVATIVE, PREPARATION METHOD FOR SAME, AND USES THEREOF - The present invention relates to an alkyne derivative, a preparation method for same, and applications thereof in medicine. Specifically, the present invention relates to the alkyne derivative as represented by formula (I), the preparation method for same, a pharmaceutically acceptable salt thereof, and uses of them as a therapeutic agent, specifically as a phosphoinositide 3-kinase γ (PI3Kγ) inhibitor, where the definitions of the substituents in formula (I) are identical to the definitions in the description. | 2022-08-18 |
20220257603 | COMBINATION THERAPY FOR TREATING MTAP-DEFICIENT TUMORS - Provided herein are methods of treating patients with a combination of an anti-folate agent and an A2BR antagonist. Also provided are methods of treating patients with a combination of an anti-folate agent and an immune checkpoint inhibitor. The patients are selected for treatment based on having an MTAP-deficient cancer. | 2022-08-18 |
20220257604 | COMPOSITIONS AND METHODS FOR MODULATING VIRAL INFECTIONS BY REGULATING GLUCOSYLCERAMIDES - Provided are methods and compositions for inhibiting viral infections. In some embodiments, the methods include administering to a subject infected with and/or at risk for infection with a virus a composition having a glucosylceramidase inhibitor, a glucosylceramide synthase inhibitor, or any combination thereof via a route and in an amount effective for treating and/or inhibiting the viral infection in the subject. Also provided are methods for inhibiting viral infections of cells, methods for inhibiting endosomal fusion of viruses in cells, and compositions for use in treating and/or inhibiting viral infections of subjects and/or cells. | 2022-08-18 |
20220257605 | NOVEL USE OF PYRROLOPYRIDINE DERIVATIVES FOR PREVENTING OR TREATING INFLAMMATORY DISEASES - The present invention relates to a pharmaceutical composition for preventing and/or treating inflammatory disease, the composition comprising a pyrrolopyridine-derivative compound as an active ingredient; the compound represented by Chemical Formula 1 according to the present invention, enantiomers thereof or pharmaceutically acceptable salts thereof, which have excellent inhibitory activity against not only protein kinases but also inflammatory factors and inflammatory cytokines; therefore a pharmaceutical composition comprising the same as an active ingredient may be useful in prevention, treatment and/or improvement of inflammatory disease, in particular but not limited to inflammatory bowel disease, rheumatoid arthritis, or lupus. | 2022-08-18 |
20220257606 | METHOD FOR TREATMENT OF MUSCULAR DYSTROPHY - Disclosed herein are compositions that inhibit adipogenesis of a fibro/adipogenic precursor (FAP) cell and methods relating to treating, preventing, reducing, and/or inhibiting a muscular degenerative condition a muscular degenerative condition comprising administering said inhibitors. | 2022-08-18 |
20220257607 | FORMULATIONS AND DOSAGES FOR ADMINISTERING A COMPOUND THAT INHIBITS MCL1 PROTEIN - Formulations of compounds of Formula I are provided as are doses and dosing regimens useful in methods of treating cancer including hematological malignances such as acute myelogenous leukemia, multiple myeloma, and non-Hodgkin's lymphoma. | 2022-08-18 |
20220257608 | Dry Powder Treprostinil for the Treatment of Pulmonary Hypertension - A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil. | 2022-08-18 |
20220257609 | TREATING CANCER WITH A CCK RECEPTOR INHIBITOR AND AN IMMUNE CHECKPOINT INHIBITOR - Provided herein are methods for treating a cholecystokinin (CCK) receptor-expressing cancerous tumor in a subject. The methods comprising administering to the subject an effective amount of a CCK receptor inhibitor and an effective amount of an immune checkpoint inhibitor, wherein the CCK receptor inhibitor inhibits one or more CCK receptors selected from the group consisting of a CCK-A receptor, a CCK-B receptor and a CCK-C receptor, and wherein the immune checkpoint inhibitor is a programmed cell death protein 1 (PD1) inhibitor or a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor. | 2022-08-18 |
20220257610 | Enhancing drug activity through accentuated buccal/sublingual administration. - The invention describes an approach to sublingual administration of drugs where in pharmacologically inactive adjuvant have been used to transport the drugs rapidly to the tissue receptor sites to create a faster and a much greater response compared to oral administration or sublingual administration of the same drugs without the use of adjuvant. These compounds enhance the passage of the drug through the buccal mucosa and transfer to the active site. Here we have enhanced the activity of glipizide and alprazzolam by their use. In the first case the activity of glipizide is enhanced 32 times and in the 2 | 2022-08-18 |
20220257611 | A METHOD OF MANUFACTURING A PHARMACEUTICAL COMPOSITION COMPRISING NEFOPAM AND ACETAMINOPHEN, AND THE PHARMACEUTICAL COMPOSITION OBTAINED THEREBY - The present invention relates to a method of preparing a pharmaceutical composition comprising acetaminophen and nefopam, said method comprises
| 2022-08-18 |
20220257612 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE - Described herein are methods for identifying or diagnosing Alzheimer's disease or poor cognition in a subject or population of subjects by analyzing biomarkers. In one aspect, the biomarkers comprise liver function enzymes or metabolites including alanine aminotransferase (ALT), aspartate aminotransferase (AST), ratio of ALT to AST, alkaline phosphatase, albumin, bilirubin, cholesterol and cholesterol metabolites, amino acids, phospholipids, bile acids, or other metabolites. In another aspect, the biomarkers comprise alanine aminotransferase (ALT), aspartate aminotransferase (AST), or the ratio of ALT to AST levels. In another aspect, the marker comprises the genotype of the ALT or AST enzymes. | 2022-08-18 |
20220257613 | DISPERSIBLE TABLETS OF ABIRATERONE ACETATE - The present invention relates to a dispersible tablet comprising at least 70% w/w of abiraterone acetate based on the total weight of the tablet and at least one pharmaceutically excipient selected from group consisting of diluents, binders, surfactants, glidants, disintegrants, lubricants, sweeteners and flavorants and further relates to the process for the preparation thereof. | 2022-08-18 |
20220257614 | USE OF 12-LIPOXYGENASE INHIBITORS IN THE TREATMENT OF COVID-19 - The present disclosure provides methods of treatment of coronavirus disease 2019 (COVID-19) based on the administration of 12-LO (12-LO) inhibitors. | 2022-08-18 |
20220257615 | COMBINATION FOR THE TREATMENT OF INFECTIONS CAUSED BY MYCOPLASMA GENITALIUM - The present invention relates to methods for treating bacterial infections caused by or associated with | 2022-08-18 |
20220257616 | COMPOSITIONS FOR MAINTAINING OR MODULATING MIXTURES OF ETHER LIPID MOLECULES IN A TISSUE OF A HUMAN SUBJECT - Provided herein is a composition comprising a mixture of ether lipid molecules of Formula (I) as defined herein. The composition is for invivo maintenance of ether lipids at levels and/or ratios associated with a non-disease state, or wherein the composition is for in vivo modification of ether lipids towards levels and/or ratios associated with a non-disease state. Also provided herein are methods of assessing subject for metabolic disease or dyslipidemia, comprising measuring relative abundance of one or more ether lipid side chains in a biological sample from a subject, methods of preventing or treating disorders such as metabolic disease or dyslipidemia, or methods of preventing conditions such as obesity and asthma, particularly in infants, involving administering a composition as defined herein. | 2022-08-18 |
20220257617 | COMPOSITIONS AND METHODS FOR KELOIDLESS HEALING - Provided are compositions, methods, and devices for reducing scarring during healing of a tissue wound. The compositions and methods involve use of sphingosine-1-phosphate (S1P), and/or an expression vector that encodes sphingosine kinase1 (SphK1). The compositions can be combined with other agents and implements, such as biocompatible nanoparticles, and medical devices involved with promoting wound healing. The approaches can reduce formation or prevent the occurrence of keloids. | 2022-08-18 |
20220257618 | USE OF THYROID BETA-AGONISTS - Methods useful for treating X-linked adrenoleukodystrophy are provided. | 2022-08-18 |
20220257619 | LONG-ACTING FORMULATIONS OF TENOFOVIR ALAFENAMIDE - The present disclosure provides long-acting formulations of tenofovir alafenamide, methods of making the same and methods of using the same. | 2022-08-18 |
20220257620 | USE OF CERTAIN PHOSPHATIDYLCHOLINES CONTAINING LONG CHAIN POLYUNSATURATED FATTY ACIDS AS NEUROPROTECTIVE AGENTS - The invention relates to compositions containing certain phosphatidylcholines containing long chain polyunsaturated fatty acids in the sn-1 position or both the sn-1 and sn-2 positions as a neuroprotective agent, and further to treating or preventing oxidative stress in a neuronal tissue with such compositions. | 2022-08-18 |
20220257621 | CANCER CELL PROLIFERATION SUPPRESSION AGENT AND COMPOSITION FOR SUPPRESSING PROLIFERATION OF CANCER CELLS - A cancer cell proliferation suppression agent containing, as an active ingredient, an inositol derivative in which a sugar is bound to inositol is provided. Furthermore, a composition for suppressing proliferation of cancer cells containing the above-mentioned cancer cell proliferation suppression agent and a pharmaceutically acceptable carrier is provided. | 2022-08-18 |
20220257622 | COMPOSITION FOR MAINTAINING LACTOBACILLUS DOMINANCE - The present invention provides compositions and formulations capable of maintaining or promoting the growth of certain strains of | 2022-08-18 |
20220257623 | NEW CATECHOLAMINE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE - The present invention provides compounds of formula (I) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease. | 2022-08-18 |
20220257624 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASE - The invention described herein relates to oral dosage form therapies for treating metabolic disorders using combinations of inhibitors of SGLT1 and SGLT2. In such dosage forms, SGLT1 is effective in the intestinal lumen, and is either not absorbed, or poorly absorbed, while the SGLT2 inhibitor inhibits sugar reabsorption in the kidney by inhibiting SGLT2 activity. Metabolic disorders treated by combined SGLT1 and SGLT2 oral dosage forms include disorders associated with abnormal accumulation of liver lipids, which may also be copresent with hyperglycemia. Combinations of SGLT1 and SGLT2 inhibitors are contemplated herein, particularly combinations | 2022-08-18 |
20220257625 | COMPOSITION AND METHODS FOR THE TREATMENT OF SKIN CONDITIONS - The present disclosure provides compositions and methods of use thereof for the treatment of skin diseases and disorders or periodontal disease. The compositions comprise cannabidiol, derivatives or pharmaceutical salts thereof, and ascorbic acid. The formulations may also include an anti-inflammatory agent, such as glucosamine. | 2022-08-18 |
20220257626 | TREATMENT COMPRISING SGLT INHIBITORS - The invention relates to methods for treating, preventing, or ameliorating a liver disease, e.g. NASH, comprising administering to a subject in need thereof a therapeutically effective amount of a SGLT inhibitor, e.g. SGLT 1/2 inhibitor. | 2022-08-18 |
20220257627 | Pemafibrate Dosing Regimens - To provide a medicament for safely treating a patient in need of treatment with pemafibrate, a salt thereof, or a solvate of any of these (hereinafter also referred to as pemafibrate therapy). | 2022-08-18 |
20220257628 | ONCE-DAILY TREATMENT OF PULMONARY FIBROSIS - A compound of formula (I) for use in a method for treatment of pulmonary fibrosis in a human including administering, with a dry powder inhaler, once-a-day to the narrowest parts of the lung tissue of the human an amount of the compound of formula (I) effective to treat the pulmonary fibrosis. | 2022-08-18 |
20220257629 | COMPOSITIONS AND METHODS FOR UPREGULATION OF HUMAN FETAL HEMOGLOBIN - Provided herein are compositions and methods for increasing fetal hemoglobin in a subject in need thereof. Also provided are compositions and methods for treating a hemoglobin disorder in a subject. | 2022-08-18 |
20220257630 | ADMINISTRATION OF STING AGONIST AND CHECKPOINT INHIBITORS - The present disclosure provides methods, pharmaceutical compositions, and kits for treating cancer in patients in need thereof. The methods comprise administering to a patient in need a STING (stimulator of interferon genes) agonist, such as Compound No. 14 as defined in the description, or a pharmaceutically acceptable salt thereof, in combination with one or more checkpoint inhibitors. Also provided are medicaments for use in treating cancer. | 2022-08-18 |
20220257631 | THERAPEUTIC RNA FOR OVARIAN CANCER - Disclosed herein are compositions, uses, and methods for treatment of ovarian cancers. In one aspect, provided herein is a composition or medical preparation comprising at least one RNA, wherein the at least one RNA encodes the following amino acid sequences:
| 2022-08-18 |
20220257632 | MICROLUMENAL TARGETING OF CANCER CELLS - The disclosure provides methods and compositions for microlumen targeting in the treatment of cancers characterized by solid tumors or cell clusters, such as circulating tumor cell (CTC) clusters and disseminated tumor cell (DTC) clusters. The methods and compositions specifically target epigen in microlumenal space between two or more cancer cells and reduce the expression, functionality and/or concentration of epigen within the microlumenal space. The methods and compositions can be part of methods of treating cancer in a subject wherein the cancer is characterized by a solid tumor, a circulating tumor cell (CTC) cluster, and/or a disseminated tumor cell (DTC) cluster. The reduced levels of functional epigen in the microlumen result in reduced incidence of metastasis and increased susceptibility of the tumor cells to additional therapeutic interventions. | 2022-08-18 |
20220257633 | METHOD OF TREATING AGE-RELATED MACULAR DEGENERATION - The present invention relates to a method of treating age-related macular degeneration. In particular embodiments, the invention relates to methods of treating age-related macular degeneration in a subject in need thereof, the method comprising the step of decreasing the expression or activation of a toll-like receptor in the subject. | 2022-08-18 |
20220257634 | COMPOSITIONS AND METHODS FOR ENHANCING INNATE IMMUNITY IN A SUBJECT FOR TREATMENT OF INFECTIONS AND CANCER AND OTHER ACUTE AND CHRONIC CONDITIONS OF THE EYE - Embodiments of the present invention generally relate to novel immunostimulatory compositions of use to stimulate non-specific immune responses in a subject. In certain embodiments, immunogenic compositions disclosed herein can be directed to use in the eye of a subject. In some embodiments, the immunogenic compositions disclosed herein enhance non-specific immune responses in the eye of a subject to treat or reduce the risk of onset of an eye condition. In other embodiments, compositions disclosed herein can be used to treat eye infections due to a microorganism, tumors of the eye, as well as, chronic wounds or infections of the eye. In some embodiments, immunogenic ocular formulations disclosed herein include combinations of agents for prolonged exposure to the eye for improved outcomes. | 2022-08-18 |
20220257635 | INJECTABLE NUTRITIONAL SUPPLEMENT - An aqueous injectable nutritional supplement composition for livestock, comprising: an EDTA complex of one or more trace elements; vitamin B | 2022-08-18 |
20220257636 | REDUCTION OF BONE RESORPTION, ESPECIALLY IN CHRONIC JOINT DISEASES - A TLR7/8 inhibitor for reduction of bone resorption, especially in chronic joint diseases, and to a pharmaceutical composition including the inhibitor. A method for predicting the severity of the course of disease of rheumatoid arthritis in a patient. | 2022-08-18 |
20220257637 | METHODS FOR TREATING OR PREVENTING OBESITY AND BODY WEIGHT MANAGEMENT - This disclosure provides a method of administrating to a subject a two-portion solution system in a specific ingesting order to yield a water-insoluble cross-linked hydrogel mass in the stomach. The volume of the formed water-insoluble cross-linked hydrogel mass is at least 50% v/v of the total volume of the two-portion solution system. The method is useful for preventing and treating overweight and obesity. | 2022-08-18 |
20220257638 | ANTITUMOR APPLICATION OF POLYSACCHARIDE CARBON NANOGELS - The present invention provides a polysaccharide carbon nanogel exhibiting antitumor efficacy prepared by carbonizing the polysaccharide utilizing dry heating. The polysaccharide carbon nanogel comprises a graphene-like nanosheet and a polysaccharide, which are complexed to form a cross-linked supramolecular structure. The polysaccharide carbon nanogels has an exceptional polyphenolic structure and high antimetastatic acitivity, which can become a promising anti-tumor drug. | 2022-08-18 |
20220257639 | TREATMENT OF PATIENTS UNDER ANTIPLATELET MEDICATION EXPERIENCING ACUTE BLEEDING COMPLICATIONS DURING/AFTER SURGERY - The invention pertains platelet endothelial aggregation receptor 1 (PEAR1) agonist for use in the treatment of bleeding in a patient wherein the patient is under antiplatelet medication. Provided is also a topical haemostat, a sealant, or an adhesive, to be used locally during surgery. | 2022-08-18 |
20220257640 | NUTRITIONAL FORMULATION FOR CANCER PREVENTION - A nutritional supplement containing specific natural ingredients and composition to target cancer vulnerability. The supplement includes between 100 to 300 mg Fucoidan, between 5 and 20 mg Lutein, between 5 and 20 mg Lycopene, between 100 and 300 mg Curcumin, between 5 and 20 mg Astaxantin, between 10 and 100 mg of Siberian Chaga extract powder and between 50 and 200 mg Vitamin C, natural vitamin C from Acerola Cherry, Astaxanthin extract (96%), Curcumin (95%), Lycopene extract (96%), Lutein extract (80%), Siberian Chaga extract, and Fucoidan extract from a brown algae, | 2022-08-18 |
20220257641 | A COMPOSITION COMPRISING SIMETHICONE AND SUCROSE ESTERS AND USE THEREOF AS AN ANTIFOAM AGENT - The present invention relates to a composition, preferably for oral use, comprising a simethicone and sucrose esters (sucrester) and, optionally, at least one food or pharmaceutical grade additive and/or excipient. Furthermore, the present invention relates to said composition for use in a method for the treatment of disorders of the gastrointestinal tract, in particular of intestinal colics, especially in paediatric subjects and in neonates, abdominal cramps, flatulence, tympanites, aerophagia, swelling of the abdomen, dyspeptic disorders (or dyspepsia) and disorders that require a reduction in gastric emptying time. Lastly, the present invention relates to the non-therapeutic use of said composition as antifoam. | 2022-08-18 |
20220257642 | METHODS AND COMPOSITIONS FOR GENERATING NITRIC OXIDE AND USES THEREOF TO DELIVER NITRIC OXIDE VIA THE RESPIRATORY TRACT - A combination, kit or composition is disclosed, comprising: (i) one or more nitrite salt; (ii) a proton source comprising one or more acid selected from organic carboxylic acids and organic non-carboxylic reducing acids; and (iii) one or more organic polyol. On reaction of the one or more nitrite salt with the proton source in the presence of the one or more organic polyol, the combination, kit or composition provides reaction products which include nitric oxide, optionally other oxides of nitrogen and/or optionally precursors thereof and which are useful in the treatment of various disorders via delivery of the combination or composition or the nitric oxide, optionally other oxides of nitrogen and/or optionally precursors thereof to a subject via the respiratory tract. | 2022-08-18 |
20220257643 | Long Chain Fatty Acid Compound Colloidal Sulfur Formulations Comprising Functional Ingredients For Acne Treatment And Other Application - Disclosed herein are compositions suitable for topical application to the skin of a mammal for the purpose of treating or preventing a skin condition or for daily use in the maintenance of healthy skin comprising colloidal sulfur as a primary or sole active pharmaceutical ingredient, present in the composition, typically in high concentrations (above 5%), along with one or more long chain fatty acids or long chain fatty acid compounds, and optionally additional functional ingredients, such as squalane, silicone(s), or both, the compositions capable of providing detectable or significant anti-fungal activity, anti-yeast activity, anti-bacterial activity, anti-pruritic activity, and anti-inflammatory activity. In some respects, the compositions described herein are capable of providing one, some or each of detectable or significant anti-fungal activity, anti-yeast activity, anti-bacterial activity, anti-pruritic activity, and anti-inflammatory activity. | 2022-08-18 |
20220257644 | STABILIZED ACTIVE OXYGEN-GENERATING ANTISEPTIC COMPOSITIONS, IRRIGATION SOLUTIONS, AND ARTICLES - A stabilized active oxygen-generating antiseptic composition is disclosed including at least one of an antiseptic mixture or an antiseptic polymer. The antiseptic mixture includes a persulfate distributed in a matrix of a sulfate wherein the antiseptic composition is characterized by a ratio of the sulfate to the persulfate of at least 8:2. The antiseptic polymer is formed by the reaction of a sulfate, a persulfate, and amino acid in a reaction solution having a ratio of the sulfate to the persulfate of at least 6:4 and a ratio of the amino acid to the sulfate and the persulfate combined of 1:2 to 2:1. An antiseptic irrigation solution is disclosed including the antiseptic composition dispersed in a solvent. An antiseptic article is disclosed including an article and at least one of the antiseptic composition or an antiseptic coating formed from the antiseptic composition disposed on a surface of the article. | 2022-08-18 |
20220257645 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC BONE DISEASES, CONTAINING BENTONITE AS ACTIVE INGREDIENT - Provided is a pharmaceutical composition for preventing or treating metabolic bone diseases, containing bentonite as an active ingredient. The present disclosure relates to a composition for inhibiting bone resorption of osteoclasts and simultaneously, promoting bone formation of osteoblasts to be usable in the prevention or treatment of metabolic bone diseases such as osteoporosis, osteomalacia, osteopenia and bone atrophy. | 2022-08-18 |
20220257646 | COMPOSITIONS AND METHODS FOR TREATING SKIN CONDITIONS - Provided herein are methods and compositions for the treatment or prevention of a skin disease (e.g., acne) in a subject by administering to the subject a composition comprising iron or cobalt. | 2022-08-18 |
20220257647 | PHARMACEUTICAL FORMULATION OF ARSENIC TRIOXIDE - Liquid fill matrices comprising dissolved arsenic trioxide and having not more than 20% aqueous component and at least 80% nonaqueous component, wherein the components are miscible, are described as well as processes of preparing such liquid fill matrices and processing the liquid fill matrices into dosage forms including soft capsules; for the treatment of various ailments, such as cancer and GVHD. | 2022-08-18 |
20220257648 | Therapeutic Human Mast Cells, Compositions, and Methods of Treating a Tumor Comprising Administering Autologous Human Mast Cells from Adipose Tissue - This disclosure is directed to mast cells obtained from adipose derived stem cells and sensitized with immunoglobulin-E targeted to a cancer antigen; compositions comprising mast cells obtained from adipose derived stem cells and sensitized with immunoglobulin-E targeted to a cancer antigen; and methods of treating a tumor in a subject, comprising administering to a subject a therapeutically effective amount of mast cells obtained from adipose derived stem cells, wherein the mast cells are autologous to the subject and sensitized with immunoglobulin-E targeted to a cancer antigen. | 2022-08-18 |
20220257649 | COMBINATION THERAPIES FOR MULTIPLE MYELOMA - Compositions and methods are provided to treat and prevent cancers, such as myelomas, and include adoptive cell therapies in combination with an IL-15 superagonist and one or more chemotherapeutic agents. | 2022-08-18 |
20220257650 | MARROW INFILTRATING LYMPHOCYTES (MILs) EXPRESSING CHIMERIC ANTIGEN RECEPTORS (CAR), METHOD OF MANUFACTURING SAME, AND METHOD OF USING IN THERAPY - Marrow-infiltrating lymphocytes (“MILs”) comprising a chimeric antigen receptor (“CAR”) are provided. In some aspects, the embodiments relate to a method for making a recombinant MIL, comprising obtaining bone marrow comprising MILs; and transfecting, transforming, or transducing the MILs with a nucleic acid encoding a chimeric antigen receptor, resulting in a CAR-MIL. In some aspects, the embodiments relate to a method for treating a condition in a subject, comprising administering to the subject a MIL comprising a C | 2022-08-18 |
20220257651 | METHODS AND DELIVERY OF ALLOGENEIC CELL PRODUCTS - The present invention relates to methods for selecting at least one drug product from a cell bank that recognizes a combination of at least one specific disease-associated antigenic peptide with at least one unique human leucocyte antigen (HLA) molecule which closely matches the HLA allele-specific expression profile of a subject. The invention also provides methods for treating a diseased cell expressing at least one disease-associated antigen which comprises the determination of the HLA allele-specific expression profile of the disease cell and the , and the selection and administration of at least one drug product. The invention also relates to a cell bank comprising a plurality of disease-associated antigen-specific T cell subpopulations, each subpopulation of T cells being primed by a plurality of subpopulations of antigen presenting cells (APCs), each subpopulation of APCs being genetically modified to express a unique HLA molecule which presents a specific disease-associated antigenic peptide. | 2022-08-18 |
20220257652 | METHODS OF USE FOR CAR T CELLS - The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells wherein the CAR T cells comprise a CAR and the CAR comprises an E2 anti-fluorescein antibody fragment, and administering to the patient a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods. | 2022-08-18 |
20220257653 | CHIMERIC ANTIGEN RECEPTORS CONTAINING GLYPICAN 2 BINDING DOMAINS - The present disclosure is directed to chimeric antigen receptors binding to Glypican 2, nucleic acids encoding the same, and cells expressing the same, and methods of using such cells to treat cancers that express or overexpress the Glypican 2 antigen. | 2022-08-18 |
20220257654 | ANTIGEN-SPECIFIC T CELL BANKS AND METHODS OF MAKING AND USING THE SAME THERAPEUTICALLY - Embodiments of the disclosure include methods of identifying and selecting suitable donors for use in constructing donor minibanks of antigen-specific T cell lines; donor minibanks of antigen-specific T cell lines; and donor banks made up of a plurality of such minibanks. The present disclosure includes methods of treating a disease or condition comprising administering at least one antigen-specific T cell line from such a donor minibank or donor bank to patient (e.g., who has received transplanted material from a transplant donor in a transplant procedure), and methods for selecting the best HLA-matched antigen-specific T cell line in the donor minibank for a particular patient. | 2022-08-18 |
20220257655 | ENGINEERED OFF-THE-SHELF IMMUNE CELLS AND METHODS OF USE THEREOF - Aspects of the present disclosure relate to methods and compositions related to the preparation of immune cells, including engineered immune cells. Certain embodiments of the disclosure include compositions, cells, and methods related to engineered invariant natural killer T (iNKT) cells for off-the-shelf use for clinical therapy. The iNKT cells may be produced from hematopoietic stem progenitor cells and may be suitable for allogeneic cellular therapy because they are HLA negative. In some aspects, the cells have imaging and suicide targeting capabilities. | 2022-08-18 |
20220257656 | SPECIFIC MARKER FOR IDENTIFYING T CELLS SPECIFICALLY ATTACKING CANCER CELLS - The present disclosure provides a specific marker for identifying T cells specifically attacking cancer cells and the utilization of the marker. According to the present disclosure, a marker that has a high specificity for identifying T cells specifically attacking cancer cells is provided. According to the present disclosure, treatment or prevention of cancer in a subject with the use of a cell subpopulation contained in a tumor tissue infiltrating CD106 | 2022-08-18 |
20220257657 | MANIPULATION AND USE OF ANTIGEN-SPECIFIC REGULATORY T CELLS - Compositions and methods are provided for isolating, manipulating and using for therapeutic and other purposes, mammalian, MHC Class I restricted, antigen-specific regulatory T cells. The regulatory T cells can be characterized as CD8+ cells that specifically suppress the responses of self-reactive and/or pathogenic CD4+ T cells by cytotoxic mechanisms including, without limitation, perform, other components of the perforin/granzyme apoptosis pathway, etc. The regulatory T cells are antigen-specific, but are not activated by the same antigen as the self-reactive and/or pathogenic CD4+ T cells. In humans the regulatory T cells express inhibitory KIR proteins, e.g. one or more of KIR2DL2, KIR2DL3, and KIR3DL1. | 2022-08-18 |
20220257658 | Combination Therapy with Gold Controlled Transgenes - Control Devices are disclosed including RNA destabilizing elements (RDE) combined with transgenes, including Chimeric Antigen Receptors (CARs) in eukaryotic cells. These RDEs can be used to optimize expression of transgenes, e.g., CARs, in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered at desired times from the eukaryotic cell. Such CAR T-cells with transgene payloads can be combined with the administration of other molecules, e.g., other therapeutics such as anticancer therapies. | 2022-08-18 |
20220257659 | CHIMERIC ANTIGEN RECEPTOR - The present invention provides a chimeric antigen receptor (CAR) which binds a target antigen having a bulky extracellular domain, wherein the CAR comprises a Fab antigen binding domain. The present invention also provides nucleic acid sequences and constructs encoding such a CAR, cells expressing such a CAR and their therapeutic uses. | 2022-08-18 |
20220257660 | RECOMBINANT erIL-15 NK CELLS - Systems and methods are presented that provide for improved NK cell function. In preferred aspects, NK-92 cells express recombinant er/LSP-IL-15 to so render the NK-92 cells independent of exogenous cytokines and to provide extracellular immune stimulation. | 2022-08-18 |
20220257661 | PREPARATIONS COMPRISING MESENCHYMAL STEM CELLS AND CANNABINOIDS AND METHODS OF THEIR USE - Disclosed are compositions comprising a MSC secretome preparation and cannabinoids and methods of the use of said compositions for the treatment of inflammatory conditions. | 2022-08-18 |
20220257662 | NERVOUS SYSTEM CELL THERAPY - The present invention relates to methods for regenerating nervous system tissue or treating a neurological disorder by administration of a therapeutically effective amount of synthetic tissue containing a cell population of one or more nervous system cell types (e.g., neurons) or multipotent cells (e.g., mesenchymal stem cells), where the cell population is embedded within a modular synthetic hydrogel that is biocompatible. In some preferred embodiments the modular synthetic hydrogel includes a PEG hydrogel crosslinked with a glycosaminoglycan such as hyaluronan. | 2022-08-18 |
20220257663 | PHOTORECEPTORS AND PHOTORECEPTOR PROGENITORS PRODUCED FROM PLURIPOTENT STEM CELLS - Methods are provided for the production of photoreceptor cells and photoreceptor progenitor cells from pluripotent stem cells. Additionally provided are compositions of photoreceptor cells and photoreceptor cells, as well as methods for the therapeutic use thereof. Exemplary methods may produce substantially pure cultures of photoreceptor cells and/or photoreceptor cells. | 2022-08-18 |
20220257664 | METHOD FOR REGULATION OF SELECTIVE DIFFERENTIATION OF MUSCULOSKELETAL STEM CELLS - The present disclosure is novel musculoskeletal stem cells (MSSCs) derived from embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs), and a medium composition for selectively differentiation into bone, tooth, cartilage, ligament and muscle, and a method for inducing differentiation thereof. | 2022-08-18 |
20220257665 | APPLICATION OF ANTIARRHYTHMIC AGENTS TO STEM CELL DERIVED CARDIOMYOCYTES AND USES THEREOF - The present invention relates to an antiarrhythmic agent for use in a method for the treatment of heart failure by transplantation of stem cell-derived cardiomyocytes, an antiarrhythmic cardiomyocyte cell population, a method for obtaining the antiarrhythmic cardiomyocyte cell population by in vitro exposure of stem cell derived cardiomyocytes to antiarrhythmic agent, and/or medical use of the antiarrhythmic cardiomyocyte cell population in the prevention of arrhythmia and treatment of heart failure. Specifically, the present invention relates to the transplantation of an antiarrhythmic cardiomyocyte cell population or co-administration of antiarrhythmic agent in vivo with transplanted stem cell derived cardiomyocytes. | 2022-08-18 |